AI SummaryIndia's pharmaceutical contract manufacturing sector — worth ₹1.2+ crore annually — faces critical quality control gaps, exemplified by the Lupin founder's discovery of contamination in outsourced vats. A third-party pharma manufacturing audit service addresses this ₹800–1,200 crore market opportunity by offering GMP compliance verification, contamination testing, and certification to contract manufacturers and pharma firms. With ~10,000 registered pharma manufacturers (40% outsourcing production), recurring audit demand is strong. The timing is right in 2026 as global pharma supply chains demand certified suppliers and Indian contract manufacturers compete on quality. Ideal for ex-pharma QA heads, certified lab directors, or regulatory consultants with GMP expertise.
Loading...